Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Gross Margin (2020 - 2025)

Gyre Therapeutics (GYRE) has disclosed Gross Margin for 6 consecutive years, with 94.67% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin fell 157.0% to 94.67% in Q3 2025 year-over-year; TTM through Sep 2025 was 95.48%, a 75.0% decrease, with the full-year FY2024 number at 96.33%, up 41.0% from a year prior.
  • Gross Margin was 94.67% for Q3 2025 at Gyre Therapeutics, down from 95.7% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 96.95% in Q2 2024 to a low of 2.16% in Q4 2021.
  • A 5-year average of 64.59% and a median of 95.49% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: plummeted -8227bps in 2021, then skyrocketed 9599bps in 2023.
  • Gyre Therapeutics' Gross Margin stood at 2.16% in 2021, then soared by 2287bps to 47.35% in 2022, then surged by 101bps to 95.4% in 2023, then increased by 0bps to 95.78% in 2024, then decreased by -1bps to 94.67% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Gross Margin are 94.67% (Q3 2025), 95.7% (Q2 2025), and 95.95% (Q1 2025).